



IMP Update- NEUTRAL

March 18, 2025



Ms. Chi Luong

(+84 28) 7300 7000 - Ext: 1042

chihtk@acbs.com.vn

Company Update

Recommendation

NEUTRAL
HSX: IMP
Pharmaceuticals
Target price (VND) 48,200

Current price (VND) 47,400

Expected share price return 1.8%

Expected dividend yield 2.1%

Expected total return 3.9%

Stock performance (%)

	YTD	1M	3M	12M
Absolute	0.2	0.2	-0.9	61.1
Relative	-5.2	-3.7	-6.1	54.3

Source: Bloomberg



Ownership

SK and related parties (KBA, Binh Minh Kim)	64.8%
Vietnam Pharmaceutical Corp.	22.0%

Stock Statistics 17-Mar-25

Bloomberg code IMP VN

52-week range (VND) 29,136-56,500

Shares O/S (m) 154

Mkt cap (VND bn) 7,254

Mkt cap (USD m) 282

Foreign room left (%) 25.6

Est. free float (m) 11.6

3m avg daily vol (shrs) 189,153

VND/USD 25,680

Index: VNIndex / HNX 1334.7/246.7

IMEXPHARM CORP (IMP VN)

The company retained growth of 10.6% YoY in net revenue and 7.1% YoY in EAT in 2024, from the high bases earlier. 2025 EAT is expected to generate decent growth of 18% YoY given that the company may continue to foster high-value products, advanced production standards, and impact from higher depreciation due to incorporation of IMP4 would normalize. Our target price for the stock by YE2025 is VND48,200/share, equivalent to a total return of 3.9%. Rating **NEUTRAL**.

IMP announced (unaudited) net revenue at VND2,205bn (+10.6% YoY) and EAT at VND321bn (+7.1% YoY) in 2024, reflecting a normalization following stunning growth in 2022-2023. Sales of finished goods captured almost 100% of its net revenue.

Net revenue growth was driven by a jump (of 45% YoY in our estimate) in the hospital channel, which outpaced the pharmacy channel and become IMP's largest earner. The pharmacy channel was estimated to fall by 7% YoY, including a 74% YoY rise in retail chains – whose share in IMP's pharmacy sales was still humble at 9% in 2024.

Value growth, thanks to increased demand for high-value products, has facilitated the expansion of production at its EU-GMP certified factories (i.e IMP2, IMP3, besides the new addition of IMP4) despite dull volume growth (details on the consumption side were unavailable). Antibiotics remain their most crucial products, accounting for 76% of IMP's sales.

Divergence in EAT and revenue growth was attributed to a squeeze in gross margin, primarily due to higher depreciation as IMP4 came online from 3Q2023. However, this impact was offset notably by a well-controlled SG&A expenses to net revenue ratio.

The company is working to set up a new EU-GMP factory - IMP5, aiming at more complicated drugs beyond antibiotics (e.g cardiovascular, diabetes, etc.). The factory is expected to start construction in 3Q2025 and go into operation in Dec 2028 – 1Q2030.

Net revenue and EBT growth (EAT was unavailable) reached 18% YoY and 16% YoY respectively in 2M2025. While the hospital channel sustained vigorous growth of 32% YoY, the pharmacy channel also witnessed improvements with 18% YoY sales growth.

Outlook: We project that the company may deliver VND2,510bn of net revenue (+13.8% YoY) and EAT of VND372bn (+15.9% YoY) in 2025, fueled by the company's continued investments in high-value products, advanced production standards, and that impact from higher depreciation due to incorporation of IMP4 would normalize.

	2023	2024U	2025F	2026F	2027F
Net Sales (VNDbn)	1,994	2,205	2,510	2,833	3,208
Growth	21.3%	10.6%	13.8%	12.9%	13.2%
EBITDA (VNDbn)	446	504	570	647	736
EBITDA margin	22.4%	22.9%	22.7%	22.8%	22.9%
NPATMI (VNDbn)	300	321	372	427	489
Growth	34.1%	7.1%	15.9%	14.8%	14.7%
EPS (bonus-adjusted, VND)	1,709	1,830	2,121	2,435	2,792
Growth	45.6%	7.1%	15.9%	14.8%	14.7%
ROE	15.1%	15.0%	16.2%	16.8%	17.2%
ROA	12.8%	13.1%	14.3%	14.8%	14.9%
Net debt/EBITDA (times)	(0.3)	(0.4)	(0.4)	(0.2)	(0.1)
EV/EBITDA (times)	16.2	14.3	12.6	11.1	9.8
PER (times)	28.2	26.3	22.7	19.8	17.3
DPS (VND)	1,000	1,000	1,000	1,000	1,000
Dividend yield	2.1%	2.1%	2.1%	2.1%	2.1%

Outperforming peers despite growth normalizing in 2024

IMP announced (unaudited) net revenue at VND2,205bn, up by 10.6% YoY in 2024, outperforming some peers such as DHG, TRA, DBD, DMC although growth has normalized from the high bases in 2022-2023 when demand rebounded strongly post-Covid.

2024 business results	Revenue	Revenue growth	EAT	EAT growth
DHG	4,885	-2.6%	779	-25.9%
TRA	2,337	1.6%	257	-9.8%
IMP	2,205	10.6%	321	7.1%
DMC	1,889	9.9%	203	10.6%
DBD	1,728	4.6%	275	2.2%

Source: Companies' financial statements; ACBS

EAT reached VND321bn, +7.1% YoY. The divergence in EAT and revenue growth was attributed to a squeeze in gross margin, primarily due to higher depreciation as IMP4 came online from 3Q2023. However, a well-controlled SG&A expenses to net revenue ratio supported the earnings.

IMP's business results	2024	+/- YoY	Key drivers
Net revenue	2,205	+10.6%	The hospital channel sustained strong performance despite stagnant pharmacy sales.
Gross profit	856	+5.5%	Higher depreciation due to incorporation of IMP4 factory; Material costs rose by 8% YoY with API prices increasing by 3% on average; Low production volume in 1H2024.
Gross margin	38.8%	-1.8 ppt	
SG&A expenses	440	+2.3%	Enhanced cost efficiency.
SG&A/net revenue	20.0%	- 1.5 ppt	
EAT	321	+7.1%	

Source: IMP; ACBS


The hospital channel was the growth driver

The hospital channel reported 45% YoY net revenue growth, in contrast to a 7% YoY decline in the pharmacy channel in 2024, in our estimate. The hospital channel turned to IMP's largest earner capturing 55% of the total, aligning with the company's target to expand this channel.


Maintained investments in advanced production standards was one of catalysts that enabled IMP to record a strong upturn of 73.3% YoY in tender value in tier 1 (*) and 29.5% YoY in tier 2 in 2024. Tier 2 still occupied the largest share in the company's tender value into the hospital channel.

(*) Tier 1 includes (i) branded drugs or (ii) produced on EU-GMP (or equivalent) lines at SRA/EMA countries or with MA (Marketing authorization license) granted by SRA countries. Tier 2 including drugs produced on EU-GMP (or equivalent) lines in Vietnam or ICH countries.

Revenue by channel



IMP's tender value by drug tier




Source: IMP; ACBS


Value growth transcended volume growth

Despite dull volume growth – the common state in the industry in recent years – a dramatic expansion of production at the company's EU-GMP certified factories (i.e IMP2, IMP3, besides the new addition of IMP4) was spurred by value growth, as a result of increased demand for high-value products. Their product portfolios have been shifting towards high-tech, high-value products comprising injectable and dispersible medicines; in which, injectable medicines raised their contribution to 33% of the total revenue in 2024 from 26% in 2023. IMP currently owns 12 EU-GMP certified production lines, highest among Vietnamese pharmaceutical companies and favoring the company in bidding to hospitals. Antibiotics remain their most crucial products, accounting for 76% of IMP's sales.

Production volume and value growth of IMP factories



Total revenue growth of factories



Source: IMP; ACBS

2025 Forecast and Valuation

IMP will still put a priority on investments in advanced production standards, R&D to reinforce its position and competitiveness in the hospital channel, while expansion in the pharmacy channel, especially retail chains may continue. We expect that the company may deliver VND2,510bn of net revenue (+13.8% YoY) and EAT of VND372bn (+15.9% YoY) in 2025, fueled by the company's continued investments in

high-value products, advanced production standards, and that impact from higher depreciation due to incorporation of IMP4 would normalize. The government's encouragement and regulations on boosting domestically produced drugs and the industry development (e.g. no tender for import drugs that have at least 03 capable local manufacturers in accordance with Circular No.03/2024/TT- BYT; Amended Pharmacy Law No. 44/2024/QH15, etc.) may also benefit the company.

Combining the DCF and PER methods, our **target price for IMP by YE2025 is VND48,200 /share.**

IMP FINANCIALS MODEL	Price (VND):	47,400	Target (VND):	48,200	Mkt cap (VND bn):	7,254
(VND bn except where stated)	2023	2024U	2025F	2026F	2027F	
Total Net Sales	1,994	2,205	2,510	2,833	3,208	
<i>Sales growth (%)</i>	<i>21.3%</i>	<i>10.6%</i>	<i>13.8%</i>	<i>12.9%</i>	<i>13.2%</i>	
CoGS ex-dep'n	1,111	1,253	1,432	1,617	1,832	
Selling expenses ex-dep'n	304	307	350	395	448	
G&A expenses ex-dep'n	115	124	137	150	165	
Financial revenues	8	5	4	5	5	
Financial expenses	26	22	25	28	32	
EBITDA	446	504	570	647	736	
<i>EBITDA margin (%)</i>	<i>22.4%</i>	<i>22.9%</i>	<i>22.7%</i>	<i>22.8%</i>	<i>22.9%</i>	
Depreciation	83	106	108	114	121	
Operating profit	364	399	462	533	615	
<i>Operating profit margin (%)</i>	<i>18.2%</i>	<i>18.1%</i>	<i>18.4%</i>	<i>18.8%</i>	<i>19.2%</i>	
Other profits/losses	3	1	0	0	0	
Profits/Losses from associates	-	-	-	-	-	
Net interest expense	(11)	(4)	(6)	(5)	(1)	
<i>as % of avg net debt</i>	<i>4.9%</i>	<i>2.4%</i>	<i>2.7%</i>	<i>2.6%</i>	<i>1.3%</i>	
<i>Interest cover (x)</i>	<i>(33)</i>	<i>(91)</i>	<i>(72)</i>	<i>(104)</i>	<i>(492)</i>	
Tax	78	83	97	111	127	
<i>Effective tax rate (%)</i>	<i>20.8%</i>	<i>20.7%</i>	<i>20.6%</i>	<i>20.6%</i>	<i>20.6%</i>	
Minority interest	-	-	-	-	-	
NPATMI	300	321	372	427	489	
Cash earnings	382	426	480	541	610	
Total number of shares	70,038,449	154,042,762	154,042,762	154,042,762	154,042,762	
EPS (VND) (after treasury shares)	3,760	1,830	2,126	2,440	2,794	
Bonus factor (x)	0.45	1.00	1.00	1.00	1.00	
Adjusted EPS (VND)	1,709	1,830	2,126	2,440	2,794	
<i>EPS growth (%)</i>	<i>45.6%</i>	<i>7.1%</i>	<i>16.2%</i>	<i>14.5%</i>	<i>14.7%</i>	

KEY CASHFLOW AND BS ITEMS	2023	2024U	2025F	2026F	2027F
Increase in working capital	318	116	116	122	141
Capex	61	90	90	300	300
Change in investment in affiliates	0	-4	0	0	0
Other cashflow items	-82	-86	-84	-85	-85
Free cash flow	-79	138	190	34	85
Share issues	-	-	-	-	-
Dividends paid	67	70	154	154	154
Increase in net debt	145	-68	-36	120	69
Net debt, end of year	-150	-218	-254	-134	-65
Shareholders' equity	2,085	2,183	2,401	2,674	3,009
BVPS (VND)	29,778	14,175	15,589	17,360	19,538
Net debt / equity (%)	-7.2%	-10.0%	-10.6%	-5.0%	-2.2%
Net debt / EBITDA (x)	-0.3	-0.4	-0.4	-0.2	-0.1
Total assets	2,393	2,505	2,686	3,079	3,484

KEY RETURN AND VALUATION RATIOS	2023	2024U	2025F	2026F	2027F
ROE	15.1%	15.0%	16.2%	16.8%	17.2%
ROA	12.8%	13.1%	14.3%	14.8%	14.9%
ROIC	16.5%	16.3%	17.8%	18.0%	17.8%
WACC	8.2%	8.2%	8.2%	8.2%	8.2%
EVA	8.3%	8.1%	9.6%	9.8%	9.6%
PER (x)	28.2	26.3	22.7	19.8	17.3
EV/EBITDA (x)	16.2	14.3	12.6	11.1	9.8
EV/FCF (x)	-91.6	52.2	37.8	211.4	85.1
PBR (x)	1.6	3.4	3.1	2.8	2.5
PSR (x)	3.7	3.4	3.0	2.6	2.3
EV/sales (x)	3.6	3.3	2.9	2.5	2.2
PEG (x, 3 yr prospective)	1.2	2.1	1.5	1.3	1.2
Dividend yield	2.1%	2.1%	2.1%	2.1%	2.1%

CONTACTS

Ho Chi Minh City Head Office

117 Nguyen Dinh Chieu, Dist. 3, Ho Chi Minh City
Tel: (+84 28) 7300 7000
Fax: (+84 28) 7300 3751

Hanoi Office

10 Phan Chu Trinh, Hoan Kiem Dist., Ha Noi
Tel: (+84 4) 3942 9395
Fax: (+84 4) 3942 9407

RESEARCH DEPARTMENT

Head of Research

Trang Do

(+84 28) 7300 7000 (x1041)
trangdm@acbs.com.vn

Manager – Properties

Truc Pham
(+84 28) 7300 7000 (x1043)
trucptt@acbs.com.vn

Manager – Financials

Hung Cao
(+84 28) 7300 7000 (x1049)
hungcv@acbs.com.vn

Manager – Retail, Technology

Chi Luong
(+84 28) 7300 7000 (x1042)
chiltk@acbs.com.vn

Associate – Oil & Gas

Hung Phan
(+84 28) 7300 7000 (x1044)
hungpv@acbs.com.vn

Associate – Industrials

Trung Tran
(+84 28) 7300 7000 (x1045)
trungtn@acbs.com.vn

Associate – Macro & Money Market

Minh Trinh Viet
(+84 28) 7300 7000 (x1046)
minhtvh@acbs.com.vn

Associate - Logistic

Hung Nguyen
(+84 28) 7300 7000 (x1047)
hungnt@acbs.com.vn

Associate – Utilities

Toan Pham
(+84 28) 7300 7000 (x1051)
toanpd@acbs.com.vn

Analyst – Technical

Huu Vo
(+84 28) 7300 7000 (x1052)
huvvp@acbs.com.vn

Analyst – Market data

Anh Mai
(+84 28) 7300 7000 (x1110)
anhmd@acbs.com.vn

INSTITUTIONAL CLIENT DIVISION

Director

Huong Chu

(+84 28) 7300 7000 (x1083)
huongctk@acbs.com.vn
groupis@acbs.com.vn

Associate

Huynh Nguyen

(+84 28) 7300 6879 (x1088)
huynhntn@acbs.com.vn

DISCLAIMER

Our Recommendation System

BUY: prospective 12 month VND total return (including dividends) will be more than 20%.

e: prospective 12 month VND total return (including dividends) will be 10% to 20%.

NEUTRAL: prospective 12 month VND total return (including dividends) will be -10% to 10%.

UNDERPERFORM: prospective 12 month VND total return (including dividends) will be will be -20% to -10%.

SELL: prospective 12 month VND total return (including dividends) will be lower than -20%.

Analyst Certification(s)

We, the author(s) of this report, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures

ACBS and/or an affiliate thereof (hereby collectively called ACBS) did or may seek to do business with companies covered in this report as its routine business. ACBS's proprietary trading accounts may have a position in such companies' securities. As a result, the investor should be aware that ACBS may have a conflict of interest from time to time.

ACBS produces a variety of research products including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research products, whether as a result of differing time horizons, methodologies, or otherwise.

Disclaimer

This report is provided for information purposes only. ACBS makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this report. ACBS will not treat unauthorized recipients of this report as its clients. Prices shown (if any) are indicative and ACBS is not offering to buy or sell or soliciting offers to buy or sell any financial instrument. **Without limiting any of the foregoing and to the extent permitted by law, in no event shall ACBS, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this report or its contents.** Other than disclosures relating to ACBS, the information contained in this report has been obtained from sources that ACBS believes to be reliable, but ACBS does not represent or warrant that it is accurate or complete. The views in this report are subject to change, and ACBS has no obligation to update its opinions or the information in this report.

Some parts of this report reflect the assumptions, views and analytical methods of the analysts who prepared them, and ACBS is not responsible for any error of their works and assumptions. ACBS may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report.

The analyst recommendations in this report reflect solely and exclusively those of the author(s), and such opinions were prepared independently of any other interests, including those of ACBS. This report does not constitute personal investment advice or take into account the individual financial circumstances or objectives of the investors who receive it. The securities discussed herein may not be suitable for all investors. ACBS recommends that investors independently evaluate each issuer, securities or instrument discussed herein and consult any independent advisors they believe necessary. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This report may not be distributed to the public media or used by the public media without prior written consent of ACBS. Otherwise it will be considered as illegal. The breacher shall compensate fully to ACBS any loss or damage which arises from such breach (if any).

In the event that the distribution and/or receipt of this report is prohibited by the investor's jurisdiction, the investor shall dismiss this report immediately otherwise it will be at his/her own risks.

ACBS does not provide tax advice and nothing contained herein should be construed to be tax advice. Accordingly, the investors should seek advice based on their particular circumstances from an independent tax advisor. This report may contain links to third-party websites. ACBS is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this report and is not incorporated by reference into this report. The inclusion of a link in this report does not imply any endorsement by ACBS. Access to any third-party website is at the investor's own risks, and the investor should always review the terms and privacy policies at third-party websites before submitting any personal information to them. ACBS is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

© Copyright ACBS (2025). All rights reserved. No part of this report may be reproduced in any manner without the prior written permission of ACBS.